Hot-Lab QC · Literature Radar
Per-batch release testing — radio-TLC, radio-HPLC, %RCP, USP 823, Eur.Ph. breakthrough monographs. Curated daily from Europe PMC (PubMed + PMC + preprints) and OpenAlex — free-full-text link on each open-access paper.
Bender A, Mower B, Buckway B, Yap J.
Radiometals have emerged as a critical tool for positron emission tomography. These radionuclides provide the opportunity for theranostic pairs, using the same compound with different radionuclides co…
Sachdeva A, Mitra JB, Pati B, Kumar A et al.
PurposeFor early detection of infections, timely treatment, and to help limit the growing problem of antibiotic resistance, there is a need for sensitive and specific infection imaging agents. Additio…
Jia F, You H, Li X, Cheng L et al.
Fibroblast activation protein (FAP) is a promising pan-tumor target for theranostics, but current FAP-targeted radioligands are limited by insufficient tumor retention and suboptimal therapeutic doses…
Ramos-Membrive R, Gil-Viciano I, Saldaña P, Maymó-Garrido S et al.
PurposeEnsuring patient and staff safety in nuclear medicine requires robust quality assurance and radiation protection systems. Radiopharmacists (RPhs) and medical physicists (MPs) play complementary…
Hudait AK, Chattopadhyay S, Barua L.
Abstract Sodium pertechnetate (Na 99m TcO 4 ) is a versatile radiopharmaceutical in nuclear medicine and frequently eluted from Molybdenum-99 -Technitium-99m ( 99 Mo- 99m Tc) generators. Its 6-hour ha…
Cini O, Miranda A, Willocx D, Karakasidi A et al.
Background Cysteine cathepsin L (CatL) is emerging as a key biomarker of cancer progression, making it an attractive candidate for non-invasive molecular imaging. To monitor enzymatic activity directl…
D. Coll Segarra, S. Arias Soriano, S.V. Tipnis, J.A. Nye
INTRODUCTION: A practical approach is presented to reliably detect and quantify the long-lived contaminant 177m Lu commonly found in 177 Lu-based therapeutics. OBJECTIVE: The objective of this work wa…
Larkina M, Yanovich G, Hasnowo LA, Varvashenya R et al.
Non-invasive radionuclide molecular imaging of epidermal growth factor receptor (EGFR) expression can guide patient stratification for EGFR-targeted therapies. The designed ankyrin repeat protein (DAR…
Dhimen A, Assfeld X, Karcher G, Collet C et al.
The development of hybrid bifunctional chelators (BFCs) capable of efficiently coordinating both diagnostic and therapeutic radionuclides remains a major challenge in theranostic radiopharmaceutical d…
Lunev AS, Petrosova KA, Rakhimov MG, Uspenskaia AA et al.
Preclinical models play a critical role in the development of PSMA-targeted radiopharmaceuticals for prostate cancer. However, many existing models have practical limitations, including slow tumor gro…
Challan SB, Khater SI, Hassan HM, Mansour MA et al.
Staphylococcus aureus infections, particularly methicillin-resistant strains, pose major diagnostic challenges in differentiating septic from aseptic inflammation. This study aimed to radiolabel diosm…
Kraihammer M, Decristoforo C, Knoll A, Zavvar TS et al.
Abstract Background We report on comparison of two automated production processes for radiolabelling and formulation of three different radiopharmaceuticals [ 177 Lu]Lu-PSMA I&T, [ 177 Lu]Lu-DOTA-TATE…
Romero-Zayas I, de Arcocha-Torres M, Peñuelas I, Martínez Montalbán E et al.
This guide outlines the radiopharmaceutical procedure for the in vitro labelling of leukocytes. Scintigraphy using leukocytes labeled with [99mTc]Tc-exametazime or [111In]In-oxine is a highly valuable…
Schietinger M, Sahnoun SEM, Krug EJ, Loewe PN et al.
Therapeutic resistance and limited brain penetration remain major challenges in high-grade gliomas. Protein-based nanocarriers, such as the heavy chain of human ferritin (FTH1), facilitate transferrin…
Espino López R, Quiroga Castro CC, Boudjemeline M, Martinez LMA.
The development and validation of analytical methods are critical to ensure the quality, safety, and efficacy of radiopharmaceutical products. This study describes the development and comprehensive va…
Wang A, Florea A, May JN, Ahmed Z et al.
Nanomedicines are increasingly employed in oncology. However, their efficacy is limited by heterogeneous nanoparticle accumulation in different tumors and patients. Nuclear imaging offers non-invasive…
Minges P, Matthias J, Domogalla LC, Thomas B et al.
Objectives : Fluorescence-guided surgery (FGS) targeting prostate-specific membrane antigen (PSMA) holds promise for improving surgical precision in prostate cancer. Since conjugation of fluorescent d…
Spahn MA, Van Loy T, Deroose CM, Celen S et al.
Background/Objectives : The chemokine receptor CXCR4 plays a pivotal role in tumor progression, metastasis, and therapy resistance and is frequently overexpressed in hematologic malignancies, includin…
Laouameria AN, Máthé D, Kubovje A, Vajdovich P et al.
Background/Objectives: Palladium-103 (¹⁰³Pd) is an Auger electron-emitting radionuclide with nanometer-scale penetration ranges that result in highly localized energy deposition, making it well suited…
Zemmouri SY, Ferradji F, Chakouri M, Nebchi EM.
ObjectivesHospital radiopharmacy plays a central role in ensuring the quality, safety and regulatory compliance of radiopharmaceuticals used for diagnostic and therapeutic purposes. Given the complexi…
Gaddis K, Roach B, Copping R, Griswold J et al.
Actinium-225 (t1/₂ = 9.92 days) is an important radioisotope for targeted alpha therapy applications. The limited supply obtained through the decay of thorium-229 has motivated accelerator-based produ…
Yamaguchi H.
Maintenance-induced configuration drift detected during a 3-lot validation study is described, highlighting the role of nuclear medicine technologists and site engineers in its resolution. A radio-hig…
Claude G, Balzer M, Brenner W, Bruchertseifer F et al.
BackgroundAnalytical data for 225Ac-labeled radiopharmaceuticals are currently obtained using thin-layer chromatography and high-performance liquid chromatography, the latter followed by offline fract…
McAdoo A, Jouad K, Rosenthal EL, Rosenberg AJ.
BackgroundThe clinical translation of molecularly targeted therapeutics and imaging agents represents a cornerstone of precision oncology, with the global theranostics market projected to exceed $25 b…
Wohlfart S, Roettgen HG, Junker N, Augustin VA et al.
Purpose We aimed to evaluate the ex-vivo early-phase spatial drug distribution of intravitreally applied bevacizumab and vancomycin in human and porcine eyes with a native vitreous body compared to vi…
La Rosa F, Guzzardi MA, Conti G, Petroni D et al.
Purpose Interaction of gut microbiota (GM) with dietary sugars (glucose, sorbitol) and choline has been transversely implicated in the pathogenesis of multiple chronic diseases. Our aim was to develop…
Perrin O, Benkhoris S, Vanney J, Barthelemi L et al.
Background Prostate cancer is a highly prevalent malignancy, and PET imaging targeting prostate-specific membrane antigen (PSMA) has become essential for assessing recurrence, metastatic spread and el…
Petzinna SM, Küppers J, Schemmer B, Jamin RN et al.
Background Assessing disease activity in giant cell arteritis (GCA) remains challenging, as existing clinical, laboratory and imaging biomarkers lack specificity. This proof-of-concept study explored …
Schädlich J, Selg C, Haase-Kohn C, Ullrich M et al.
Dicarbadodecaboranes (12) (carboranes) are versatile molecular building blocks with unique properties, which allow the expansion of classical medicinal-chemical space. To enable single-photon emission…
Thakral P, Rana N, Uppal A, Koley M et al.
BackgroundMetastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge, particularly in patients with suboptimal response to ¹⁷⁷Lu-PSMA-617. Terbium-161 (Tb-161), with its e…
Humpert S, Mues L, Pedersen NB, Neumaier F et al.
Astatine-211 is a short-lived alpha-emitting radionuclide with high potential for cancer treatment by targeted alpha therapy (TAT). Reversed-phase high-performance liquid chromatography (RP-HPLC) is c…
Shetty PSS, Vimalnath KV, Patra S, Rakhit S et al.
Non-invasive imaging of skeletal metastases by Positron Emission Tomography (PET) for cancer prognosis, staging and treatment monitoring is one of the prominent fields of radiopharmaceutical research.…
Zhang S, Hu Q, Lu Q, Wu J et al.
Galectin-3 is associated with aggression, proliferation, and metastasis in various refractory cancers. Although galectin-3 targeted positron emission tomography (PET) tracers have shown considerable p…
Storms W, Celen S, Maes J, Serdons K et al.
Background Fibroblast activation protein inhibitor (FAPI)-based positron emission tomography (PET) radiopharmaceuticals have shown promise for imaging cancer-associated fibroblasts (CAFs), a key compo…
Bao H, Wang N, Zhu X, Chen S et al.
Despite serving as a radical alternative to surgery for inoperable colorectal hepatic metastases patients, thermal ablation faces local tumor progression rates up to 25% from residual tumors, seriousl…
Okarvi SM.
[¹⁸F]-Fluoroestradiol, which is recently approved by the FDA, is a well-recognized estrogen receptor radiopharmaceutical in nuclear medicine to investigate both primary and metastatic breast cancers. …
Patra S, Singh K, Chakraborty A, Mohammed SK et al.
Holmium-166 [T ½ = 26.8 h, E β - (max) = 1.74 MeV (48.7%) and 1.85 MeV (50.0%); Eγ = 80.6 keV (10.6%)] is one of the most promising radionuclides in radiation synovectomy (RSV) for the treatment of in…
Tomiyoshi K, Namiki Y, Yang DJ, Inoue T.
Objective: Current good manufacturing practice (cGMP) guidance for positron emission tomography (PET) drugs has been established in Europe and the United States. In Japan, the Pharmaceuticals and Medi…
Ritt P, Fernández R, Soza-Ried C, Nicolai H et al.
Purpose Several prostate-specific membrane antigen (PSMA) radiopharmaceuticals have been used for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). In an attempt to improve th…
Ghosh S, Guleria A, Patra S, Chakraborty A et al.
Purpose Enhancing therapeutic effectiveness is crucial for translating anticancer nanomedicines from laboratory to clinical settings. In this study, we have developed radioactive rhenium oxide nanopar…
Choi H, Jeong SH, Simó C, Bakenecker A et al.
Most non-muscle invasive bladder cancers have been treated by transurethral resection and following intravesical injection of immunotherapeutic agents. However, the delivery efficiency of therapeutic …
Salgueiro MJ, Portillo M, Tesán F, Nicoud M et al.
Background Previous studies employing polymeric micelles and molecular imaging for in vivo nanosystem characterization have led to the development of radionanoprobes (RNPs) designed for diagnosing and…
Gonzalez MM, Poma AL, Cuello N, Soldati AL.
Background and objectivesIn a hospital radiopharmacy with 2a operational level, including the preparation of radiopharmaceuticals from prepared and approved reagent kits, it is common to have a single…
Simó C, Serra-Casablancas M, Hortelao AC, Di Carlo V et al.
Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanob…
Greifenstein L, Gunkel A, Hoehne A, Osterkamp F et al.
Hardly any new tracers attracted more attention in nuclear medicine in the last couple of years than radiolabeled fibroblast activation protein inhibitors (FAPi' s ). Molecules targeting cancer-associ…
Okarvi SM.
Aim Angiotensin II (AngII) is known to play a significant part in the development of breast cancer by triggering cell propagation of breast cancer, tumor angiogenesis, and regulating tumor invasion an…
Leenhardt J, Choisnard L, Plasse M, Ardisson V et al.
BackgroundThe aim of this brief communication is to highlight the potential bacteriological risk linked to the processes control of radiopharmaceutical preparations made in a radiopharmacy laboratory.…
Rusu T, Delion M, Pirot C, Blin A et al.
Background c-MET is a transmembrane receptor involved in many biological processes and contributes to cell proliferation and migration during cancer invasion process. Its expression is measured by imm…
Bragina O, Chernov V, Larkina M, Rybina A et al.
The determination of tumor human epidermal growth factor receptor type 2 (HER2) status is of increasing importance with the recent approval of more efficacious HER2-targeted treatments. There is a lac…
Larenkov A, Mitrofanov I, Pavlenko E, Rakhimov M.
The radiolytic degradation of vector molecules is a major factor affecting the shelf life of therapeutic radiopharmaceuticals. The development of time-stable dosage forms of radiopharmaceuticals is th…
Daniel T, Balouzet Ravinet C, Clerc J, Batista R et al.
Background [⁶⁸Ga]Ga-PentixaFor is a promising radiotracer for positron emission tomography imaging of several human tumors overexpressing the chemokine receptor-4 (CXCR4). CXCR4 overexpression has bee…
Nelson BJB, Andersson JD, Wuest F, Spreckelmeyer S.
BackgroundThe radiometal gallium-68 (⁶⁸Ga) is increasingly used in diagnostic positron emission tomography (PET), with ⁶⁸Ga-labeled radiopharmaceuticals developed as potential higher-resolution imagin…
Armando M, Barthélémi L, Couret I, Verdier C et al.
BackgroundRadiopharmaceuticals preparation unit, such as every aseptic preparation units, are strictly monitored in terms of microbiological contamination. Despite all biocontamination control procedu…
Maisto C, Aurilio M, Morisco A, de Marino R et al.
The aim of this work is to compare [⁶⁸Ga]Ga-PSMA-11 and [¹⁸F]PSMA-1007 PET/CT as imaging agents in patients with prostate cancer (PCa). Comparisons were made by evaluating times and costs of the radio…
Bzowski P, Borys D, Gorczewski K, Chmura A et al.
Background ¹²⁴I Iodine (T[Formula: see text] = 4.18 d) is the only long-life positron emitter radioisotope of iodine that may be used for both imaging and therapy as well as for ¹³¹I dosimetry. Its ph…
Strating E, Wassenaar E, Verhagen M, Rauwerdink P et al.
Background In colorectal cancer (CRC), the consensus molecular subtype 4 (CMS4) is associated with therapy resistance and poor prognosis. Clinical diagnosis of CMS4 is hampered by locoregional and tem…
Donzé C, Rubira L, Kotzki PO, Deshayes E et al.
Gallium-68 radiolabeling is an increasingly common activity in radiopharmacy. Single vial cold kits to radiolabel DOTATOC and PSMA-11 with ⁶⁸Ga were developed, either for manual or automated preparati…
Silva F, D'Onofrio A, Mendes C, Pinto C et al.
Despite some progress, the overall survival of patients with glioblastoma (GBM) remains extremely poor. In this context, there is a pressing need to develop innovative therapy strategies for GBM, name…
Maisto C, Morisco A, de Marino R, Squame E et al.
Background Prostate-specific membrane antigen is overexpressed in prostate cancer and it is considered a good target for positron emission tomography/computed tomography imaging of primary cancer and …
Aguiar SI, Dias JNR, André AS, Silva ML et al.
A major bottleneck in the successful development of central nervous system (CNS) drugs is the discovery and design of molecules that can cross the blood-brain barrier (BBB). Nano-delivery strategies a…
Showing the 60 most recent of 93 papers in this topic.Browse every paper →
Request brochure
Tell us who you are and we’ll send the full product brochure to your institutional email after a quick review. We respond within one working day (Mon–Fri, 9:30–18:30 IST).
A Saxsons sales engineer will review your request and send the brochure to your institutional email within one working day. You may receive a verification call before processing.
